Cytokinetics (NASDAQ:CYTK) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

Cytokinetics (NASDAQ:CYTK) had its price target lifted by equities research analysts at Needham & Company LLC from $84.00 to $85.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Needham & Company LLC’s price objective indicates a potential upside of 35.72% from the stock’s previous close.

CYTK has been the subject of several other research reports. Citigroup reissued a “market outperform” rating on shares of Cytokinetics in a report on Monday, December 22nd. Royal Bank Of Canada lifted their price objective on Cytokinetics from $95.00 to $101.00 and gave the company an “outperform” rating in a research note on Friday, February 20th. Citizens Jmp upped their target price on Cytokinetics from $88.00 to $96.00 and gave the stock a “market outperform” rating in a research note on Wednesday. HC Wainwright raised their target price on Cytokinetics from $120.00 to $136.00 and gave the stock a “buy” rating in a report on Monday, December 22nd. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $90.00 price target on shares of Cytokinetics in a report on Friday, January 9th. Seventeen investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $88.83.

Cytokinetics Stock Down 0.4%

Cytokinetics stock opened at $62.63 on Wednesday. The stock has a 50-day moving average price of $64.21 and a 200 day moving average price of $58.38. The company has a market capitalization of $7.66 billion, a price-to-earnings ratio of -9.59 and a beta of 0.54. Cytokinetics has a 52 week low of $29.31 and a 52 week high of $70.98.

Cytokinetics (NASDAQ:CYTK) last posted its quarterly earnings results on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.02). The business had revenue of $17.76 million for the quarter, compared to the consensus estimate of $8.02 million. During the same period in the previous year, the company earned ($1.26) earnings per share. The company’s revenue was up 4.9% compared to the same quarter last year. Research analysts anticipate that Cytokinetics will post -5.24 EPS for the current fiscal year.

Insider Buying and Selling at Cytokinetics

In related news, EVP Andrew Callos sold 52,486 shares of the company’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $65.95, for a total transaction of $3,461,451.70. Following the completion of the transaction, the executive vice president owned 50,660 shares in the company, valued at $3,341,027. This represents a 50.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Edward M. Md Kaye sold 28,064 shares of the firm’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $66.72, for a total transaction of $1,872,430.08. Following the completion of the transaction, the director directly owned 9,977 shares in the company, valued at $665,665.44. This represents a 73.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 151,385 shares of company stock valued at $9,817,158. Insiders own 2.70% of the company’s stock.

Hedge Funds Weigh In On Cytokinetics

Hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in shares of Cytokinetics by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 12,048,131 shares of the biopharmaceutical company’s stock valued at $765,538,000 after acquiring an additional 191,336 shares in the last quarter. State Street Corp raised its stake in Cytokinetics by 3.7% in the 4th quarter. State Street Corp now owns 5,825,295 shares of the biopharmaceutical company’s stock valued at $370,139,000 after purchasing an additional 207,961 shares during the last quarter. Deep Track Capital LP lifted its holdings in Cytokinetics by 17.8% in the 3rd quarter. Deep Track Capital LP now owns 4,300,000 shares of the biopharmaceutical company’s stock valued at $236,328,000 after purchasing an additional 650,000 shares in the last quarter. Geode Capital Management LLC boosted its stake in Cytokinetics by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 3,056,017 shares of the biopharmaceutical company’s stock worth $194,214,000 after purchasing an additional 15,815 shares during the last quarter. Finally, Vestal Point Capital LP grew its holdings in shares of Cytokinetics by 14.8% during the second quarter. Vestal Point Capital LP now owns 2,975,000 shares of the biopharmaceutical company’s stock worth $98,294,000 after buying an additional 384,469 shares in the last quarter.

Trending Headlines about Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: HC Wainwright reiterates a “Buy” and models near‑term quarterly EPS (Q1: -$1.57, Q2: -$1.61, Q4: -$1.89) while assigning a $136 price target — a substantial upside that supports longer‑term investor interest. HC Wainwright estimates
• Positive Sentiment: Analysts have been raising price targets: Citizens JMP to $96 (market outperform), Leerink Partners to $84 (outperform), and Needham to $85 (buy) — these upgrades add upward pressure on sentiment. Benzinga price target coverage
• Positive Sentiment: Zacks notes Cytokinetics is advancing Myqorzo launch plans after FDA activity and highlights a ~$1.22B cash position, which supports funding for commercialization and 2026 catalysts. Myqorzo launch & cash runway
• Positive Sentiment: Retail/permissioned coverage and bullish opinion pieces (e.g., Villanovan profile) are promoting a buy case based on pipeline and commercialization upside. Why Cytokinetics Is a Buy
• Neutral Sentiment: Q4 earnings call and transcript coverage are available for deeper read‑throughs of management commentary on margins, SG&A, and launch timing (useful for assessing execution risk). Earnings call transcript (InsiderMonkey) Earnings transcript (Seeking Alpha) Earnings transcript (Yahoo)
• Neutral Sentiment: Reported short‑interest data appears anomalous/zero in the latest release, so there’s no clear short‑squeeze signal from those figures. (No actionable short‑pressure evidence.)
• Negative Sentiment: Q4 results showed a slightly wider-than-expected loss (EPS -$1.50 vs. estimate -$1.48) and higher expenses year‑over‑year — a near‑term negative that likely pressured the stock despite revenue outperformance. Q4 results coverage

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.